Paradigm Biopharmaceuticals Limited (ASX:PAR)
Australia
· Delayed Price · Currency is AUD 0.175
-0.020 (-10.26%)
Apr 29, 2026, 4:10 PM AEST
ASX:PAR Revenue
Paradigm Biopharmaceuticals had revenue of 25.15K AUD in the half year ending December 31, 2025. This brings the company's revenue in the last twelve months to 8.45K, down -49.40% year-over-year.
Revenue (ttm)
8.45K
Revenue Growth
-49.40%
P/S Ratio
10,425.52
Revenue / Employee
n/a
Employees
n/a
Market Cap
88.10M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Amplia Therapeutics | 5.01M |
| Botanix Pharmaceuticals | 21.92M |
| Cynata Therapeutics | 1.69M |
| Arovella Therapeutics | 3.21M |
| Radiopharm Theranostics | 16.28M |
| LTR Pharma | 1.13M |
| Immutep | 7.92M |
| Island Pharmaceuticals | 62.85K |
Paradigm Biopharmaceuticals News
- 3 years ago - Australia's Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up - GlobeNewsWire
- 4 years ago - PARADIGM BIOPHARMACEUTICALS LTD. APPOINTS MARCO POLIZZI as CHIEF EXECUTIVE OFFICER - PRNewsWire
- 4 years ago - PARADIGM BIOPHARMACEUTICALS SPOTLIGHTS POTENTIAL BREAKTHROUGH OSTEOARTHRITIS TREATMENT AT BIOLOGICAL ASSOCIATION 3RD ANNUAL SUMMIT - PRNewsWire
- 4 years ago - Paradigm Biopharmaceuticals Retains Rubenstein Public Relations as Agency of Record - PRNewsWire
- 4 years ago - FDA Grants Fast Track Designation for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program - PRNewsWire
- 4 years ago - Paradigm Biopharmaceuticals Initiates a Phase 3 Clinical Trial in Knee Osteoarthritis Across the U.S - PRNewsWire